Vestal Point Capital LP Sells 110,000 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Vestal Point Capital LP reduced its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 18.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 490,000 shares of the company’s stock after selling 110,000 shares during the quarter. Vestal Point Capital LP’s holdings in Voyager Therapeutics were worth $2,866,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of VYGR. Plato Investment Management Ltd purchased a new position in Voyager Therapeutics in the 1st quarter worth about $38,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after purchasing an additional 4,098 shares during the last quarter. Intech Investment Management LLC bought a new position in Voyager Therapeutics during the third quarter valued at approximately $74,000. SG Americas Securities LLC purchased a new stake in Voyager Therapeutics in the second quarter worth approximately $85,000. Finally, Victory Capital Management Inc. grew its position in Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after purchasing an additional 1,630 shares during the period. 48.03% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on VYGR shares. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Wedbush reduced their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partners started coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price for the company. Finally, StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 18th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Voyager Therapeutics has a consensus rating of “Buy” and an average price target of $17.00.

Voyager Therapeutics Price Performance

Shares of VYGR stock opened at $5.78 on Friday. The company has a market capitalization of $315.76 million, a price-to-earnings ratio of 8.14 and a beta of 0.89. The company’s fifty day moving average price is $6.50 and its 200-day moving average price is $7.32. Voyager Therapeutics, Inc. has a one year low of $5.19 and a one year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. The business had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the previous year, the business earned ($0.59) earnings per share. Equities research analysts expect that Voyager Therapeutics, Inc. will post -1.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.53% of the stock is owned by insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.